FeaturedMedia Release
Bisantrene Patent in US granted “Notice of Allowance”
A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent
- Posted by: Race Oncology
Media Release
Race to present at J.P. Morgan Biotech Conference in US
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief
- Posted by: Race Oncology
Media Release
Melbourne research institute in global cancer collaboration led by Swiss biotech firm
Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the
- Posted by: Race Oncology
Video
Race interview at Biotech and Money Conference
In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.
- Posted by: Race Oncology
Video
Edison TV research interview
What is Bisantrene and where did it come from? Click here to watch CEO Peter Molloy’s interview on Edison TV.
- Posted by: Race Oncology
Video
The devastating impact of AML and why we need hope
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers.
- Posted by: Race Oncology
Video
Race Oncology produces first batch of Bisantrene for sale
Race Oncology Limited (RAC) is pleased to announce it has produced its first good manufacturing practice (GMP) batch of cancer drug Bisantrene. The first batch will be enough to treat up to sixty
- Posted by: Race Oncology